ANPI Angiotech Pharmaceuticals - Common Shares (MM)

VANCOUVER, Oct. 10 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate partner Boston Scientific Corporation ("BSC") today announced the schedule of their major events and press announcements at the Transcatheter Cardiovascular Therapeutics (TCT) conference, which runs from October 16 to 21 in Washington, D.C. BSC will be announcing long-term efficacy data on its TAXUS(TM) Express(2)(TM) paclitaxel-eluting stent system, including results from the TAXUS I, II, IV and VI clinical trials, as well as data from the ARRIVE, MILESTONE II and OLYMPIA "real-world" registries. Together, these studies represent more than 38,000 patients. The TAXUS clinical trials represent the largest body of randomized drug-eluting stent data available today. BSC's participation in TCT 2005 will include 16 clinical abstracts, 20 additional scientific presentations and 2 educational symposia. "The data we will present at TCT continues to reinforce the strengths that make TAXUS the leader in the worldwide drug-eluting stent market: safety, efficacy and deliverability," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The long-term data from our TAXUS program shows a sustained efficacy benefit out to four years and an established "real-world" safety record. The quality and rigor of our clinical trials has also raised the bar regarding the use of evidence based medicine in determining treatment decisions." Schedule of Events Tuesday, October 18 ------------------- - TAXUS Long-Term Results. BSC will announce follow-up data on long-term safety and efficacy from four of its TAXUS paclitaxel-eluting stent clinical trials. Results will be presented from TAXUS I (up to four years), TAXUS II (up to three years), TAXUS IV (up to three years), and TAXUS VI (up to two years). BSC will issue a press release summarizing data from all four clinical trials. - Symposium on Drug-Eluting Stents. From 8:00-10:00 p.m., BSC will host an evening symposium entitled "Drug-Eluting Stents 2005: Challenges Overcome, Frontiers Yet to Conquer" chaired by Gregg W. Stone, M.D. and Sigmund Silber, M.D., in the Grand Ballroom of the Renaissance Hotel. Topics will include durability of DES trial results, "real-world" studies, diabetes as a risk factor for restenosis, and evidence based medicine. Speakers will include Gregg Stone, M.D., Sigmund Silber, M.D., Donald Baim, M.D., Keith Dawkins, M.D., Stephen Ellis, M.D., John Lasala, M.D., and Patrick Serruys, M.D. Wednesday, October 19 --------------------- - Evidence Based Medicine. On Wednesday, BSC will issue a press release highlighting the importance of pursuing evidence based medicine through the increased use of randomized controlled clinical trials. The release will feature comments from a symposium presentation titled "Evidence Based Medicine and Best Practices with DES", which will highlight the need for large scale, multi-center, randomized, controlled trials with a primary clinical endpoint. Thursday, October 20 -------------------- - OLYMPIA Registry. On Thursday, BSC will issue a press release announcing 30-day safety data from its OLYMPIA registry, which is designed to collect and analyze "real-world" clinical outcomes data using BSC's next-generation TAXUS(R) Liberte(TM) paclitaxel-eluting stent system in the treatment of patients with coronary artery disease. - DES Outcomes in Diabetic Patients. On Thursday, BSC will issue a press release announcing nine-month sub-population data from its TAXUS V clinical trial, detailing outcomes for its TAXUS Express(2) paclitaxel-eluting stent in the treatment of diabetic patients, particularly higher-risk insulin-requiring diabetics. BSC acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products and has co-exclusive rights to other vascular and non-vascular products. Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical company pioneering the combination of pharmaceutical compounds with medical devices and biomaterials to both create novel solutions for poorly addressed disease states and improve surgical outcomes. To find out more about Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at http://www.angiotech.com/. Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," "may" and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements. FOR ADDITIONAL INFORMATION: --------------------------- Analysts and Investors: Todd Young, Vice President Investor Relations and Communications, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Analysts: Rui Avelar, Senior Vice President Medical Affairs and Communications, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6996 Media: Wendy Carhart, Waggener Edstrom Bioscience, (503) 443-7354, Email: DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Analysts and Investors: Todd Young, Vice President Investor Relations and Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext 6933; Analysts: Rui Avelar, Senior Vice President Medical Affairs and Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext 6996; Media: Wendy Carhart, Waggener Edstrom Bioscience, (503) 443-7354, Email:

Copyright